In addition to the management of LDL-C, the treatment of atherogenic dyslipidemia, defined by elevated levels of triglycerides and apolipoprotein B, has garnered attention due to the increasing prevalence of obesity and insulin resistance [15]. Here, APOB is linked to obesity due to melanocortin 4 receptor deficiency.